Marked facial enlargement in secondary hyperparathyroidism

Marked facial enlargement in secondary hyperparathyroidism.

Brown tumours in patients with ESRD represent an extreme form of osteodystrophy. They occur most often in the long bones, ribs and pelvis, but can be found in any bone [1,2]. Clinically significant lesions in the jaws are rare [2]. We report a haemodialysis (HD) patient with a rapidly growing maxillary mass diagnosed as a brown tumour. The case is noteworthy because of the patient’s young age, ...

Intensification of Anemia by Secondary Hyperparathyroidism in Hemodialysis Patients

The excessive amounts of parathyroid hormone in secondary hyperparathyroidism (SHPTH) is suggested to interfere with normal erythropoiesis.  In SHPTH, during chronic renal failure, due to the impairment of erythropoietin synthesis, this effect is more pronounced.  In the present study the role of secondary hyperparathyroidism in the severity of anemia was evaluated in hemodialysis patients (n=3...

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Current evidence suggests that administration of 1,25(OH)2D3 to patients with chronic renal insufficiency results in suppression of secondary hyperparathyroidism only if hypercalcemia occurs. However, since the parathyroid glands possess specific receptors for 1,25(OH)2D3 and a calcium binding protein, there is considerable interest in a possible direct effect of 1,25(OH)2D3 on parathyroid horm...

Vitamin D deficiency and secondary hyperparathyroidism in pediatrics obesity

Obesity is one of the health problems in the developing and developed countries. Obesity subjects the individuals with metabolic and endocrine disorders. It is obvious that vitamin D deficiency or insufficiency may lead to secondary hyperparathyroidism. Thus, obesity increases the risk of vitamin D deficiency. Considering the high prevalence of vitamin D deficiency in children and adolescents w...

racial differences in secondary hyperparathyroidism